News & Events
10 May 2012 DIABETES AT THE COALFACE
Following on from the success of last year’s event, I am delighted to announce that the Welsh Conference of the Primary Care Diabetes Society will be held again in Cardiff on 10 May this year.
Hosted by Dr Pam Brown and Dr David Millar-Jones, Welsh representatives of the PCDS, this event will provide you with continuing professional development, an opportunity to learn from some leading diabetes experts in Wales and a chance to network with your peers and discuss the key issues that affect you in day-to-day clinical practice.
Through lectures and interactive masterclasses this event will provide practical guidance to healthcare professionals on issues that impact everyday diabetes practice in Wales. Entitled “Diabetes at the Coalface – Management strategies for type 2 diabetes in Wales”, this year’s event covers topics including:
- Diagnosing diabetes and how to screen for it
- Diabetes therapies: out with the old and in with the new?
- Obesity: a Welsh perspective
New resources due to be launched before this year’s conference will also provide you with extended CPD opportunities, such as online post-event education and tools to help you put in place action plans within your practice.
This cost to attend this event this year has been reduced to £75 for PCDS members* and £95 for non-members. However, by booking before 29 February, you can take advantage of the of the early-bird price of £60 and £75 respectively.
For more information or to book on this exciting conference please click here or call the events team on: 0207 627 1510.
We hope that you will be able to join us at this important and influential event.
A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes
Insulin pump therapy is safe and effective in the pediatric population, although in this study, the major benefit in HbA1c was seen in males. The use of advanced pump features was associated with greater improvement in HbA1c (Acta Diabetologica)
This review summarizes recent findings regarding the relationship between adipocytokines and hepatic insulin resistance (Journal of Diabetes Research)
In vivo studies validated that these formulations provided improved glucose control in type 1 diabetic mice subcutaneously administered with a degradable nano-network. A single injection of the developed nano-network facilitated stabilization of the blood glucose levels in the normoglycemic state (<200 mg/dL) for up to 10 days (ACS Nano)
Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes
It was concluded that good metabolic control can be achieved if these agents are used judiciously. The DPP-4 inhibitors improve HbA1c but are weight neutral, while the GLP-1R agonists cause both weight loss and improvements in HbA1c. The addition of insulin under specialist supervision can be beneficial (Practical Diabetes)
There was a significant increase in the incidence of diagnosed type 2 diabetes between 1991 and 2010 and the proportion of people diagnosed at an earlier age has increased markedl (Diabetes, Obesity and Metabolism)